Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07278583

Evaluation of Heart Failure Telemonitoring Eligibility Criteria

CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Clermont-Ferrand

Clermont-Ferrand, France

Location status: Recruiting

Location contact

Clément RIOCREUX

CONTACT

[email protected]

0473752489

Clément RIOCREUX

PRINCIPAL_INVESTIGATOR

About this study

After an episode of heart failure, patients have been included in a telemonitoring program in order to reduce rehospitalizations for heart failure and improve follow-up. On a daily basis, the patients weigh themselves on connected scales which enables a team of dedicated nurses to follow them closely. If need be they can call the patient, ask for a blood exam and adapt their prescription. Indeed, if remote support is insufficient, patients can be hospitalized prematurely and so decrease the duration of hospital care.

The inclusion criteria correspond to either an episode of heart failure in the last 12 months or dyspnea at least New York Heart Association (NYHA) 2 with NT-proBNP over 1000pg/mL.

The follow up is renewed every 6 months. Patients are excluded from monitoring when criteria are no longer fulfilled. As these characteristics have been chosen empirically, our aim is to see if patients no longer presenting these standards have indeed a low chance of bad evolution.

Information is gathered from their medical record at inclusion, exclusion and 1 year after exclusion. A short phone call is made after 1 year of exclusion, to appreciate their evolution and gather information concerning their symptoms, treatments ...

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adults
  • able to read and understand french
  • included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg/mL) and excluded by medical decision as no longer presenting eligibillity criteria

Exclusion criteria

  • Patients leaving telemonitoring for other reasons (choice, death, medical reason, relocation, inobservance)

Treatment and study plan

Primary outcomes

  1. Composite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure)

    Time frame: From telemonitoring exclusion up to a year after

Secondary outcomes

  1. Amount of medical appointments

    Time frame: From telemonitoring exclusion up to a year after

    General practician and cardiology consultations

  2. Natriuretic peptides, NTproBNP, evolution

    Time frame: From inclusion until a year after exclusion

    NTproBNP comparison at inclusion, exclusion and a year after exclusion for monitoring

  3. Number of patients that could theoretically be re-included during follow up

    Time frame: From telemonitoring exclusion up to a year after

  4. Determination of potential patient profiles more suitable to discontinue remote monitoring

    Time frame: From inclusion up to a year after telemonitoring exclusion

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Laclautre

CONTACT

[email protected]

334.73.754.963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Official study title

Evaluation of Eligibility Criteria for Heart Failure Telemonitoring : Analysis of CARDIAUVERGNE's Cohort

Acronym: Weigh-HF

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 12, 2025
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.